XML 37 R19.htm IDEA: XBRL DOCUMENT
v3.23.2

Share-Based Compensation | 12 Months Ended
--- | ---
Jun. 30, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract] |
Share-Based Compensation | Share-Based CompensationShare-Based Compensation Plans The Company has awards outstanding from two share-based compensation plans (the 2013 Long-Term Incentive Plan and the 2021 Long-Term Incentive Plan). The 2021 Long-Term Incentive Plan was approved at the annual meeting of the shareholders on January 27, 2022. The 2021 Plan permits the grant of any or all of the following types of awards to grantees: stock options, including non-qualified options and ISOs; SARs; restricted stock ("RSA"); deferred stock and restricted stock units ("RSU"); performance units ("PU") and performance shares; dividend equivalents; and other stock-based awards. Eligible grantees include employees, officers, non-employee consultants and non-employee directors of the Company and its affiliates. Awards are currently only being granted under the 2021 Long-Term Incentive Plan. As of June 30, 2023, there were 1,270,781 shares available for future grant under the 2021 Long-Term Incentive Plan. All of the Company’s share-based compensation plans are shareholder approved, and it is the Company’s belief that such awards align the interests of its employees and directors with those of its shareholders. An RSA is common stock that is subject to risk of forfeiture or other restrictions that lapse upon satisfaction of specified conditions. An RSU represents the right to receive shares of common stock in the future with the right to future delivery of the shares subject to risk of forfeiture or other restrictions that lapse upon satisfaction of specified conditions. A PU represents the right to receive shares of common stock in the future contingent on performance against predetermined objectives over a specified performance period. The Company accounts for its share-based compensation awards in accordance with ASC 718, Stock Compensation, which requires all share-based compensation to be recognized in the income statement based on fair value and applies to all awards granted, modified, canceled or repurchased after the effective date. Total share-based compensation included as a component of selling, general and administrative expenses in our Consolidated Income Statements was as follows:
| Fiscal Year Ended June 30,
| 2023 |  | 2022 |  | 2021
| (in thousands)
Share-based compensation related to: |  |  |  |  |
Equity classified stock options | $ | 1,426 |  |  | $ | 1,848 |  |  | $ | 1,332 |
Equity classified restricted stock | 9,793 |  |  | 9,815 |  |  | 6,707 |
Total share-based compensation | $ | 11,219 |  |  | $ | 11,663 |  |  | $ | 8,039 |
Stock Options The Company did not grant stock options during the fiscal year ended June 30, 2023 or June 30, 2022. The Company granted stock options for 640,782 shares during the fiscal year ended June 30, 2021 that vest annually over 3 years and have a 10-year contractual life. These options were granted with an exercise price that is no less than 100% of the fair market value of the underlying shares on the date of the grant. The fair value of each option (for purposes of calculation of share-based compensation) was estimated on the date of grant using the Black-Scholes-Merton option pricing formula that uses assumptions determined at the date of grant. Use of this option pricing model requires the input of subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them ("expected term"), the estimated volatility of the Company's common stock price over the expected term ("expected volatility") and the number of options that will ultimately not complete their vesting requirements ("forfeitures"). Changes in the subjective assumptions can materially affect the estimate of the fair value of share-based compensation and, consequently, the related amount recognized in the Consolidated Income Statements. The Company used the following weighted-average assumptions for the options granted in fiscal year ended June 30, 2021:
| Fiscal Year Ended June 30,
| 2021 |  |
Expected term | 5 years |  |
Expected volatility | 42.78% |  |
Risk-free interest rate | 0.36% |  |
Dividend yield | 0.00% |  |
Weighted-average fair value per option | $9.01 |  |
The weighted-average expected term of the options represents the period of time the options are expected to be outstanding based on historical trends and behaviors of certain groups and individuals receiving these awards. The expected volatility is predominantly based on the historical volatility of our common stock for a period approximating the expected term. The risk-free interest rate reflects the interest rate at grant date on zero-coupon United States governmental bonds that have a remaining life similar to the expected option term. The dividend yield assumption was based on the Company's dividend payment history and management's expectations of future dividend payments. A summary of activity under our stock option plans is presented below:
| Fiscal Year Ended June 30, 2023
| Options |  | Weighted- Average Exercise Price |  | Weighted- Average Remaining Contractual Life |  | Aggregate Intrinsic Value
Outstanding, beginning of year | 1,123,099 |  |  | $ | 32.23 |  |  |  |  |
Granted during the period | — |  |  | — |  |  |  |  |
Exercised during the period | (36,435) |  |  | 25.00 |  |  |  |  |
Canceled, forfeited, or expired during the period | (59,993) |  |  | 27.70 |  |  |  |  |
Outstanding, end of year | 1,026,671 |  |  | 32.76 |  |  | 4.57 |  | $ | 2,113,985 |
Vested and expected to vest at June 30, 2023 | 1,026,460 |  |  | 32.76 |  |  | 4.57 |  | $ | 2,112,871 |
Exercisable, end of year | 855,834 |  |  | $ | 34.28 |  |  | 4.01 |  | $ | — |
The aggregate intrinsic value was calculated using the market price of the Company's stock on June 30, 2023, and the exercise price for only those options that have an exercise price that is less than the market price of our stock. This amount will change as the market price per share changes. The aggregate intrinsic value of options exercised during the fiscal years ended June 30, 2023, 2022 and 2021 was $0.2 million, $0.6 million and less than $0.1 million, respectively. A summary of the status of the Company’s shares subject to unvested options is presented below:
| Fiscal Year Ended June 30, 2023
| Options |  | Weighted Average Exercise Price |  | Weighted Average Grant Date Fair Value
Unvested, beginning of year | 384,638 |  |  | $ | 25.16 |  |  | $ | 9.08 |
Granted | — |  |  | — |  |  | — |
Vested | (171,926) |  |  | 25.11 |  |  | 9.06 |
Canceled or forfeited | (41,875) |  |  | 25.51 |  |  | 9.30 |
Unvested, end of year | 170,837 |  |  | $ | 25.12 |  |  | $ | 9.06 |
As of June 30, 2023, there was approximately $0.6 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans in the form of stock options. This cost is expected to be recognized over a weighted-average period of 0.38 years. The total fair value of options vested during the fiscal years ended June 30, 2023, 2022 and 2021 is $1.6 million, $1.9 million and $0.3 million, respectively. The following table summarizes information about stock options outstanding and exercisable as of June 30, 2023:
|  | Options Outstanding |  | Options Exercisable
Range of Exercise Prices |  | Shares Outstanding |  | Weighted Average Remaining Contractual Life |  | Weighted Average Exercise Price |  | Number Exercisable |  | Weighted Average Exercise Price
$22.27 - $26.38 |  | 363,233 |  |  | 7.38 |  | 24.53 |  |  | 231,673 |  |  | 24.55 |
$26.38 - $30.49 |  | 119,021 |  |  | 7.40 |  | 27.14 |  |  | 79,744 |  |  | 27.14 |
$30.49 - $34.60 |  | 57,799 |  |  | 4.44 |  | 34.35 |  |  | 57,799 |  |  | 34.35 |
$34.60 - $38.71 |  | 207,169 |  |  | 2.83 |  | 37.71 |  |  | 207,169 |  |  | 37.71 |
$38.71 - $42.82 |  | 279,449 |  |  | 1.02 |  | 41.83 |  |  | 279,449 |  |  | 41.83 |
|  | 1,026,671 |  |  | 4.57 |  | $ | 32.76 |  |  | 855,834 |  |  | $ | 34.28 |
The Company issues shares to satisfy the exercise of options. Restricted Stock Grants of Restricted Shares During the fiscal year ended June 30, 2023, the Company granted 518,987 shares of restricted stock to employees and non-employee directors, all of which were issued in the form of RSUs:
| Fiscal Year Ended June 30, 2023
| Shares granted |  | Date granted |  | Grant date fair value |  | Vesting period
Employees |  |  |  |  |  |  |
Certain employees based on performance | 346,059 |  |  | August 26, 2022 |  | $ | 28.66 |  |  | Annually over 4 years
Certain employees based on performance | 58,323 |  |  | August 26, 2022 |  | $ | 28.66 |  |  | Annually over 3 years
Certain employees based on performance | 58,323 |  |  | August 26, 2022 |  | $ | 27.92 |  |  | Annually over 3 years
Certain employees based on performance | 815 |  |  | December 1, 2022 |  | $ | 30.70 |  |  | Annually over 4 years
Certain employees based on hire | 13,067 |  |  | June 1, 2023 |  | $ | 28.70 |  |  | Annually over 4 years
Non-Employee Directors |  |  |  |  |  |  |
Certain Directors | 42,400 |  |  | August 26, 2022 |  | $ | 28.66 |  |  | 12 months
A summary of the status of the Company’s outstanding restricted stock is presented below:
| Fiscal Year Ended June 30, 2023
| Shares |  | Weighted-Average Grant Date Fair Value
Outstanding, beginning of year | 639,342 |  |  | $ | 32.04 |
Granted during the period | 518,987 |  |  | 28.58 |
Vested during the period | (224,062) |  |  | 30.56 |
Cancelled, forfeited, or expired during the period | (44,357) |  |  | 31.29 |
Outstanding, end of year | 889,910 |  |  | $ | 30.43 |
As of June 30, 2023, there was approximately $18.4 million of unrecognized compensation cost related to unvested performance units and restricted stock units granted, which is expected to be recognized over a weighted-average period of 1.31 years. The Company withheld 79,537 shares for income taxes during the fiscal year ended June 30, 2023.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration